← Back to Analyst Consensus 
LENZ Buy
LENZ Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 2 reiterations from 2 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 21, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Oct 19, 2026 | Piper Sandler | maintain | Neutral → Neutral | — | 54% |
| Aug 12, 2026 | Piper Sandler | maintain | Neutral → Neutral | — | 54% |
| Jul 7, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 13, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| May 12, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 12, 2026 | Piper Sandler | downgrade | Overweight → Neutral | — | 54% |
| Apr 21, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 26, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Mar 25, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Oct 20, 2025 | Raymond James | reiterate | Outperform → Outperform | $50 | 54% |
| Oct 10, 2025 | Piper Sandler | maintain | Overweight → Overweight | $67 | 54% |
| Aug 1, 2025 | Citigroup | maintain | Buy → Buy | $52 | 54% |
| Aug 1, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $56 | 44% |
| Jul 31, 2025 | Citigroup | maintain | Buy → Buy | $49 | 54% |
| Jul 31, 2025 | Raymond James | maintain | Outperform → Outperform | $40 | 54% |
| Jul 28, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $48 | 44% |
| May 8, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $38 | 44% |
| Apr 16, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $38 | 44% |
| Apr 14, 2025 | Piper Sandler | maintain | Overweight → Overweight | $51 | 54% |
| Mar 20, 2025 | Citigroup | maintain | Buy → Buy | $47 | 54% |
| Nov 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $38 | 44% |
| Sep 27, 2024 | Raymond James | initiate | — → Outperform | $37 | 54% |
| Aug 15, 2024 | Piper Sandler | maintain | Overweight → Overweight | $36 | 54% |
| Aug 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $38 | 44% |
| Aug 12, 2024 | HC Wainwright & Co. | initiate | — → Buy | $38 | 44% |
| Apr 15, 2024 | Leerink Partners | initiate | — → Outperform | $32 | 51% |
| Apr 15, 2024 | William Blair | initiate | — → Outperform | $0 | 48% |
| Apr 10, 2024 | Citigroup | initiate | — → Buy | $34 | 54% |
| Mar 27, 2024 | Piper Sandler | initiate | — → Overweight | $28 | 54% |
Price Target Trend
Mar 30, 2026 Latest: $20 Oct 25, 2026
EPS Estimates
+1q $-0.88
Lo: $-1.24 Hi: $-0.64
5 analysts ▲2
+1y $-2.73
Lo: $-4.14 Hi: $-1.50
6 analysts ▲2
0q $-0.95
Lo: $-1.02 Hi: $-0.85
6 analysts ▲3
0y $-4.18
Lo: $-4.55 Hi: $-3.83
6 analysts ▲4
Cross-Platform Signals
No cross-platform signals in the last 90 days